Adverse effects of tocilizumab versus baricitinib in severe COVID-19
File(s)Letter to editor at CCM 4-7-23.docx (66.07 KB)
Accepted version
Author(s)
Leaf, David E
Gordon, Anthony C
Lawler, Patrick R
Type
Journal Article
Date Issued
2023-09-01
Date Acceptance
2023-09-01
Citation
Critical Care Medicine, 2023, 51 (9), pp.e184-e185
ISSN
0090-3493
Publisher
Lippincott, Williams & Wilkins
Start Page
e184
End Page
e185
Journal / Book Title
Critical Care Medicine
Volume
51
Issue
9
Copyright Statement
Copyright © 2023 Lippincott Williams & Wilkins, Inc. This is a non-final version of an article published in final form in Critical Care Medicine 51(9):p e184-e185, September 2023. | DOI: 10.1097/CCM.0000000000005933
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/37589523
PII: 00003246-202309000-00027
Subjects
COVID-19
COVID-19 Drug Treatment
Drug-Related Side Effects and Adverse Reactions
Humans
Iatrogenic Disease
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2023-09-01